I thank my right hon. Friend for his answer, and for his work in this area, but leaving the decision to prescribe cannabis for medical use to individual doctors while NICE is saying that more evidence is needed risks the inertia that has led the MS Society to conclude that not a single person has yet benefited from the legalisation of cannabis for medical use, except those who are able to pay up to £1,000 a month. Will my right hon. Friend meet the MS Society and me to discuss more ways of accelerating the uptake of Bedrolite among patients who have a reasonable expectation of benefiting from it?
I am very happy to meet my hon. Friend and colleagues from the MS Society. She is right to say that we need to ensure we get the evidence that the clinicians understandably want, and in fact we have committed public funds, through the National Institute for Health Research, to establish clinical trials to develop that evidence base.